| For: | Fukui H. Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites? World J Gastroenterol 2015; 21(41): 11584-11596 [PMID: 26556988 DOI: 10.3748/wjg.v21.i41.11584] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i41/11584.htm |
| Number | Citing Articles |
| 1 |
Yumi Noda, Sei Sasaki. Updates and Perspectives on Aquaporin-2 and Water Balance Disorders. International Journal of Molecular Sciences 2021; 22(23) doi: 10.3390/ijms222312950
|
| 2 |
Luis Rodrigo. Ascites - Physiopathology, Treatment, Complications and Prognosis. 2017; doi: 10.5772/intechopen.70232
|
| 3 |
Ioannis Bellos, Konstantinos Kontzoglou, Despina N Perrea. Predictors of tolvaptan short‐term response in patients with refractory ascites: A meta‐analysis. Journal of Gastroenterology and Hepatology 2020; 35(2) doi: 10.1111/jgh.14784
|
| 4 |
Hideto Kawaratani, Hiroshi Fukui, Kei Moriya, Ryuichi Noguchi, Tadashi Namisaki, Masakazu Uejima, Mitsuteru Kitade, Kosuke Takeda, Yasushi Okura, Kosuke Kaji, Norihisa Nishimura, Hiroaki Takaya, Yousuke Aihara, Yasuhiko Sawada, Shinya Sato, Kenichiro Seki, Akira Mitoro, Junichi Yamao, Hitoshi Yoshiji. Predictive parameter of tolvaptan effectiveness in cirrhotic ascites. Hepatology Research 2017; 47(9) doi: 10.1111/hepr.12826
|
| 5 |
Qi Ling, Haojiang Dai, Runzhou Zhuang, Tian Shen, Weilin Wang, Xiao Xu, Shusen Zheng. Predicting short-term survival after liver transplantation on eight score systems: a national report from China Liver Transplant Registry. Scientific Reports 2017; 7(1) doi: 10.1038/srep42253
|
| 6 |
Alessandro Peri, Dario Norello, Benedetta Fibbi. Hydro Saline Metabolism. Endocrinology 2023; doi: 10.1007/978-3-031-27119-9_8
|
| 7 |
Theodosios D. Filippatos, George Liamis, Moses S. Elisaf. Ten pitfalls in the proper management of patients with hyponatremia. Postgraduate Medicine 2016; 128(5) doi: 10.1080/00325481.2016.1186488
|
| 8 |
Yasuhiko Sawada, Makoto Shiraki, Motoh Iwasa, Atsushi Hiraoka, Hiroyuki Nakanishi, Yoshiyasu Karino, Tomoaki Nakajima, Hisamitsu Miyaaki, Takumi Kawaguchi, Hitoshi Yoshiji, Kiwamu Okita, Kazuhiko Koike. The effects of diuretic use and the presence of ascites on muscle cramps in patients with cirrhosis: a nationwide study. Journal of Gastroenterology 2020; 55(9) doi: 10.1007/s00535-020-01694-8
|
| 9 |
Alessandro Peri, Dario Norello, Benedetta Fibbi. Hydro Saline Metabolism. Endocrinology 2022; doi: 10.1007/978-3-030-44628-4_8-1
|
| 10 |
Kazuhiro Kotoh, Akihide Masumoto, Masaki Kato, Motoyuki Kohjima, Kenta Motomura, Takeshi Goya, Takeshi Senjyu, Kosuke Tanaka, Masayoshi Yada, Masayuki Miyazaki. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World Journal of Gastroenterology 2017; 23(29): 5379-5385 doi: 10.3748/wjg.v23.i29.5379
|
| 11 |
Kazuto Tajiri, Yoshiharu Tokimitsu, Hiroyuki Ito, Yoshinari Atarashi, Kengo Kawai, Masami Minemura, Satoshi Yasumura, Terumi Takahara, Yukihiro Shimizu, Toshiro Sugiyama. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis. Digestive Diseases 2018; 36(4) doi: 10.1159/000489258
|
| 12 |
|
| 13 |
E. Sbardella, A. M. Isidori, G. Arnaldi, M. Arosio, C. Barone, A. Benso, R. Berardi, G. Capasso, M. Caprio, F. Ceccato, G. Corona, S. Della Casa, L. De Nicola, M. Faustini-Fustini, E. Fiaccadori, L. Gesualdo, S. Gori, A. Lania, G. Mantovani, P. Menè, G. Parenti, C. Pinto, R. Pivonello, P. Razzore, G. Regolisti, C. Scaroni, F. Trepiccione, A. Lenzi, A. Peri. Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM). Journal of Endocrinological Investigation 2018; 41(1) doi: 10.1007/s40618-017-0776-x
|
| 14 |
Carlos G. Musso, Rossina Juarez, Richard J. Glassock. Water, electrolyte, acid–base, and trace elements alterations in cirrhotic patients. International Urology and Nephrology 2018; 50(1) doi: 10.1007/s11255-017-1614-y
|
| 15 |
Beata Kasztelan-Szczerbinska, Halina Cichoz-Lach. Refractory ascites—the contemporary view on pathogenesis and therapy. PeerJ 2019; 7 doi: 10.7717/peerj.7855
|
| 16 |
David C. Madoff, Joshua Cornman-Homonoff, Brett E. Fortune, Ron C. Gaba, Andrew J. Lipnik, Hooman Yarmohammadi, Charles E. Ray. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021; 298(3) doi: 10.1148/radiol.2021201960
|
| 17 |
Takefumi Mori, Yusuke Ohsaki, Ikuko Oba‐Yabana, Sadayoshi Ito. Diuretic usage for protection against end‐organ damage in liver cirrhosis and heart failure. Hepatology Research 2017; 47(1) doi: 10.1111/hepr.12700
|
| 18 |
Hideto Kawaratani, Hiroshi Fukui, Hitoshi Yoshiji. Treatment for cirrhotic ascites. Hepatology Research 2017; 47(2) doi: 10.1111/hepr.12769
|